CNCecilia Ndungu

Cecilia Ndungu

*This is an algorithmically generated author record based on publicly available information.

Cecilia Ndungu has a total of 4 co-authors. Here are the top co-authors by number of shared publications:

  • Abednego Moki Musyoki

    Department of Medical Laboratory Science, School of Health Sciences, Kenyatta University, Nairobi, Kenya

    1 shared publication
  • John M. Maingi

    Department of Biochemistry, Microbiology and Biotechnology, School of Pure and Applied Sciences, Kenyatta University, Nairobi, Kenya

    1 shared publication
  • Raphael Ondondo

    Department of Medical Laboratory Services, School of Public Health, Biomedical Science and Technology, Masinde Muliro University of Science and Technology, Kakamega, Kenya

    1 shared publication
  • Susan Githii

    National Public Health LaboratoryKenyatta National Hospital Grounds, Nairobi, Kenya

    1 shared publication

Latest Publications

  • Open Access

    Urinary tract infections caused by carbapenem-resistant Gram-negative bacteria among pregnant women attending antenatal care clinic at Murang’a County Referral Hospital, Kenya

    by Cecilia Ndungu, John M. Maingi, Raphael Ondondo, Susan Githii, Abednego Moki Musyoki

    Urinary tract infections (UTIs) continue to pose a significant health risk during pregnancy, with growing antimicrobial resistance making effective management increasingly challenging. Of more significance is the emergence of carbapenem-resistant (CR) bacteria, especially in resource-limited countries where diagnostic capabilities, treatment options, and comprehensive epidemiological data are inadequate. This study aimed to describe the prevalence, antimicrobial co-resistance patterns, and factors associated with UTIs caused by CR Gram-negative bacteria (GNB) among pregnant women at Murang’a County Referral Hospital in Kenya. A hospital-based cross-sectional study involving 365 pregnant women was conducted from May to October 2023. Participants were recruited through systematic random sampling; each underwent clinical evaluation. Demographic information was collected using a structured questionnaire, while clinical data were obtained from hospital records. Clean-catch midstream urine samples were processed in the hospital’s microbiology laboratory using standard microbiological techniques. The overall prevalence of UTIs was 25.5% (93/365; 95% CI: 21.01–29.95), with GNB (76.3%, 71/93) predominating. The prevalence of UTIs caused by CR-GNB and carbapenemase-producing (CP)-GNB was 4.93% (95% CI: 2.71–7.15) and 2.7% (95% CI: 1.07–4.41), respectively. Escherichia coli (E. coli) was the predominant pathogen overall (60.3%), and among CR-GNB (72.2%) and CP-GNB (60%) UTIs. More than half (10/18, 55.6%) of CR isolates co-produced extended β-lactamases (ESBLs) and carbapenemases. No colistin resistance was detected in carbapenem-resistant isolates. Co-resistance ranged from 38.5% to 92.3%, with the lowest resistance (≤ 46.2) to nitrofurantoin and aztreonam. High co-resistance (≥ 69%) was observed for most β-lactams, cephalosporins, aminoglycosides, and trimethoprim/sulfamethoxazole. 89% of CR isolates, including all CP-GNB, were multidrug-resistant. Multiple antibiotic resistance indices (0.67–0.93) were highest among CP isolates. Unmarried/single women were more likely to have UTIs caused by CP-GNB (adjusted odds ratio: 8.87; 95% CI: 1.57–50.01). Carbapenemase- and ESBL-co-producing GNB, predominated by E. coli, were present among pregnant women with UTIs. Unmarried/single status was the only variable significantly associated with CP-GNB UTIs in this study. Strengthening carbapenem stewardship and enhancing infection prevention practices are urgently needed to prevent further spread of resistant strains in the current context and beyond.